Sodium-glucose cotransporter 2 inhibitors for chronic heart failure: the ultimate solution?

European Journal of Heart FailureEarly View Invited Editorial Sodium–glucose cotransporter 2 inhibitors for chronic heart failure: the ultimate solution? Mihai Strachinaru, Corresponding Author Mihai Strachinaru [email protected] orcid.org/0000-0002-1861-5404 Department of Cardiology, Pulmonary Vascular Diseases and Heart failure Clinic, Brussels University Hospital-Erasme Hospital, Brussels, Belgium Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Corresponding author. Department of Cardiology, Brussels University Hospital-Erasme Hospital, Route de Lennik 808, 1070 Brussels, Belgium. Tel: +32 2 5553554, Email: [email protected]Search for more papers by this authorAna Roussoulières, Ana Roussoulières Department of Cardiology, Pulmonary Vascular Diseases and Heart failure Clinic, Brussels University Hospital-Erasme Hospital, Brussels, BelgiumSearch for more papers by this authorOlivier C. Manintveld, Olivier C. Manintveld Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Erasmus MC Transplant Institute, Rotterdam, The NetherlandsSearch for more papers by this author Mihai Strachinaru, Corresponding Author Mihai Strachinaru [email protected] orcid.org/0000-0002-1861-5404 Department of Cardiology, Pulmonary Vascular Diseases and Heart failure Clinic, Brussels University Hospital-Erasme Hospital, Brussels, Belgium Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Corresponding author. Department of Cardiology, Brussels University Hospital-Erasme Hospital, Route de Lennik 808, 1070 Brussels, Belgium. Tel: +32 2 5553554, Email: [email protected]Search for more papers by this authorAna Roussoulières, Ana Roussoulières Department of Cardiology, Pulmonary Vascular Diseases and Heart failure Clinic, Brussels University Hospital-Erasme Hospital, Brussels, BelgiumSearch for more papers by this authorOlivier C. Manintveld, Olivier C. Manintveld Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Erasmus MC Transplant Institute, Rotterdam, The NetherlandsSearch for more papers by this author First published: 22 June 2023 https://doi.org/10.1002/ejhf.2942 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2884. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2021 update: A report from the American Heart Association. Circulation 2021; 143: e254–e743. https://doi.org/10.1161/CIR.0000000000000950 2Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet 2018; 391: 572–580. https://doi.org/10.1016/S0140-6736(17)32520-5 3Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: A review. Diabetes Metab Res Rev 2005; 21: 31–38. https://doi.org/10.1002/dmrr.532 4Hjarne U. A study of orthoglycaemic glycosuria with particular reference to its hereditability. Acta Med Scand 1927; 67: 495–571. 5Santer R, Calado J. Familial renal glucosuria and SGLT2: From a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133–141. https://doi.org/10.2215/CJN.04010609 6Choi CI. Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: Discovery of next-generation antihyperglycemic agents. Molecules 2016; 21: 1136. https://doi.org/10.3390/molecules21091136 7Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357. https://doi.org/10.1056/NEJMoa1812389 8Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128. https://doi.org/10.1056/NEJMoa1504720 9McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008. https://doi.org/10.1056/NEJMoa1911303 10Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–1424. https://doi.org/10.1056/NEJMoa2022190 11McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4–131. https://doi.org/10.1002/ejhf.2333 12Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–1461. https://doi.org/10.1056/NEJMoa2107038 13Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387: 1089–1098. https://doi.org/10.1056/NEJMoa2206286 14Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol 2022; 21: 45. https://doi.org/10.1186/s12933-022-01480-1 15Braunwald E. SGLT2 inhibitors: The statins of the 21st century. Eur Heart J 2022; 43: 1029–1030. https://doi.org/10.1093/eurheartj/ehab765 16Packer M. SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol 2023; 20: 443–462. https://doi.org/10.1038/s41569-022-00824-4 17Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016; 18: 588–598. https://doi.org/10.1002/ejhf.497 18Pascual-Figal DA, Zamorano JL, Domingo M, Morillas H, Nuñez J, Cobo Marcos M, et al.; DAPA-MODA Study Investigators. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study. Eur J Heart Fail. https://doi.org/10.1002/ejhf.2884 Pubslished online ahead of print 21/05/23. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation